Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2/3 1

Status

Recruiting 3Unknown 1Terminated 1Approved for marketing 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 47Rectal Neoplasms 29Stomach Neoplasms 24Colorectal Neoplasms 24Triple Negative Breast Neoplasms 18Neoplasm Metastasis 10Nasopharyngeal Carcinoma 10Colonic Neoplasms 10Locally Advanced Rectal Cancer 7Esophageal Neoplasms 7Biliary Tract Neoplasms 7Brain Neoplasms 5Adenocarcinoma Of Esophagus 5Adenocarcinoma 5Pancreatic Neoplasms 4Neoplasms 4Gastrointestinal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neuroendocrine Tumors 3HER2-positive Breast Cancer 3Cholangiocarcinoma 3Advanced Solid Tumors 3Recurrence 2Neoplasm, Residual 2Meningeal Neoplasms 2Locally Advanced Colorectal Cancer 2Esophageal Squamous Cell Carcinoma 2Early Low Rectal Cancer 2Colorectal Cancer Metastatic 2

Interventions

Trastuzumab 8pyrotinib 6pertuzumab 4Docetaxel 3Capecitabine 3tucatinib 2Paclitaxel 2Neoadjuvant Therapy 2trastuzumab deruxtecan 1neratinib 1inavolisib 1Taxoids 1Isovaleryl-CoA Dehydrogenase 1Injections 1Genetic Testing 1Drug Therapy 1Carboplatin 1Blood Specimen Collection 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × HER2-positive Breast Cancer × Capecitabine × Clear all
NCT07413939 2026-05-11

BREnnA

Hoffmann-La Roche

Phase 2/3 Recruiting
650 enrolled
Breast

HER2-positive Breast Cancer

NCT06992882 2025-07-18

A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)

Fudan University

Phase 3 Recruiting
2,306 enrolled
Breast

HER2-positive Breast Cancer

NCT06217185 2024-02-28

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

Hebei Medical University Fourth Hospital

Phase 4 Recruiting
100 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡